Sam Brusco, Associate Editor03.09.23
Sight Sciences began U.S. launch of the Ergo-Series of the OMNI surgical system, which helps surgeons perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma.
The OMNI surgical system enables minimally invasive glaucoma surgery (MIGS) that addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm’s canal, and the collector channels. It can be used before, in combination with, or following cataract surgery. The new features of the Ergo-Series include:
New enhancements enable surgeons to more easily rotate and position the cannula tip within Schlemm’s canal with precise finger rotations versus wrist adjustments. The handle’s viscoelastic luer connector is now removable and detaches when the viscoelastic cartridge is removed, resulting in more clearance with the surgical microscope. The Ergo-Series cannula tip has a new profile for gentle and precise access to Schlemm's canal while continuing to enable full 360-degree catheterization.
Reay Brown, MD, a glaucoma specialist and Sight Science's chief medical officer, told the press, "The Ergo-Series maintains the same therapeutic functionality as the second-generation OMNI Surgical System. The technology enhancements provide additional benefits that enable surgeons to perform an innovative, minimally invasive glaucoma surgery."
“For me, the new cannula tip technology is the biggest improvement,” added Zarmeena Vendal, MD, glaucoma surgeon and founder of Westlake Eye Specialists in Austin, Texas. “The profile of the tip enables me to score the trabecular meshwork more confidently and makes entry into Schlemm’s canal gentler. In addition, when I deploy the catheter, I can follow the path of the Schlemm’s canal a bit more naturally. In our glaucoma surgery practice, access to the OMNI Surgical System lets us provide these new technology procedures for the benefit of our patients.”
OMNI Ergo-Series enables surgeons to provide a minimally invasive, implant-free surgery to reduce intraocular pressure in adults with primary open-angle glaucoma. The device’s indications for use, contraindications, warning, and precautions remain unchanged. OMNI is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. It can be used before, in combination with, or following cataract surgery.
Paul Badawi, CEO and co-founder of Sight Sciences, said, “OMNI is an innovative technology developed to enable a surgeon to perform a circumferential and complete outflow procedure that addresses all three known points of resistance in the aqueous outflow system through a single clear corneal incision. We are committed to continually innovating and improving our core technologies alongside our surgeon partners in order to provide the greatest benefit to patients suffering from primary open-angle glaucoma. Based on the initial feedback, we are confident the Ergo-Series of the OMNI Surgical System will continue to raise the bar.”
The OMNI surgical system enables minimally invasive glaucoma surgery (MIGS) that addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm’s canal, and the collector channels. It can be used before, in combination with, or following cataract surgery. The new features of the Ergo-Series include:
New enhancements enable surgeons to more easily rotate and position the cannula tip within Schlemm’s canal with precise finger rotations versus wrist adjustments. The handle’s viscoelastic luer connector is now removable and detaches when the viscoelastic cartridge is removed, resulting in more clearance with the surgical microscope. The Ergo-Series cannula tip has a new profile for gentle and precise access to Schlemm's canal while continuing to enable full 360-degree catheterization.
Reay Brown, MD, a glaucoma specialist and Sight Science's chief medical officer, told the press, "The Ergo-Series maintains the same therapeutic functionality as the second-generation OMNI Surgical System. The technology enhancements provide additional benefits that enable surgeons to perform an innovative, minimally invasive glaucoma surgery."
“For me, the new cannula tip technology is the biggest improvement,” added Zarmeena Vendal, MD, glaucoma surgeon and founder of Westlake Eye Specialists in Austin, Texas. “The profile of the tip enables me to score the trabecular meshwork more confidently and makes entry into Schlemm’s canal gentler. In addition, when I deploy the catheter, I can follow the path of the Schlemm’s canal a bit more naturally. In our glaucoma surgery practice, access to the OMNI Surgical System lets us provide these new technology procedures for the benefit of our patients.”
OMNI Ergo-Series enables surgeons to provide a minimally invasive, implant-free surgery to reduce intraocular pressure in adults with primary open-angle glaucoma. The device’s indications for use, contraindications, warning, and precautions remain unchanged. OMNI is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. It can be used before, in combination with, or following cataract surgery.
Paul Badawi, CEO and co-founder of Sight Sciences, said, “OMNI is an innovative technology developed to enable a surgeon to perform a circumferential and complete outflow procedure that addresses all three known points of resistance in the aqueous outflow system through a single clear corneal incision. We are committed to continually innovating and improving our core technologies alongside our surgeon partners in order to provide the greatest benefit to patients suffering from primary open-angle glaucoma. Based on the initial feedback, we are confident the Ergo-Series of the OMNI Surgical System will continue to raise the bar.”
